Endogenous Muscle Atrophy F-Box Mediates Pressure Overload–Induced Cardiac Hypertrophy Through Regulation of Nuclear Factor-κB
- 8 July 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 109 (2), 161-171
- https://doi.org/10.1161/circresaha.110.238717
Abstract
Rationale: Overexpression of muscle atrophy F-box (MAFbx/atrogin-1), an E3 ubiquitin ligase, induces proteasomal degradation in cardiomyocytes. The role of endogenous MAFbx in regulating cardiac hypertrophy and failure remains unclear. Objective: We investigated the role of MAFbx in regulating cardiac hypertrophy and function in response to pressure overload. Transverse aortic constriction (TAC) was applied to MAFbx knockout (KO) and wild-type (WT) mice. Methods and Results: Expression of MAFbx in WT mice was significantly increased by TAC. TAC-induced increases in cardiac hypertrophy were significantly smaller in MAFbx KO than in WT mice. There was significantly less lung congestion and interstitial fibrosis in MAFbx KO than in WT mice. MAFbx KO also inhibited β-adrenergic cardiac hypertrophy. DNA microarray analysis revealed that activation of genes associated with the transcription factor binding site for the nuclear factor-κB family were inhibited in MAFbx KO mice compared with WT mice after TAC. Although the levels of IκB-α were significantly decreased after TAC in WT mice, they were increased in MAFbx KO mice. MAFbx regulates ubiquitination and proteasomal degradation of IκB-α in cardiomyocytes. In primary cultured rat cardiomyocytes, phenylephrine-induced activation of nuclear factor-κB and hypertrophy were significantly suppressed by MAFbx knockdown but were partially rescued by overexpression of nuclear factor-κB p65. Conclusions: MAFbx plays an essential role in mediating cardiac hypertrophy in response to pressure overload. Downregulation of MAFbx inhibits cardiac hypertrophy in part through stabilization of IκB-α and inactivation of nuclear factor-κB. Taken together, inhibition of MAFbx attenuates pathological hypertrophy, thereby protecting the heart from progression into heart failure.Keywords
This publication has 31 references indexed in Scilit:
- Sent to DestroyCirculation Research, 2010
- Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin‐binding entitiesEMBO Reports, 2009
- Divergent Tumor Necrosis Factor Receptor–Related Remodeling Responses in Heart FailureCirculation, 2009
- Distinct roles of GSK-3α and GSK-3β phosphorylation in the heart under pressure overloadProceedings of the National Academy of Sciences of the United States of America, 2008
- Proteasome inhibition promotes regression of left ventricular hypertrophyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteinsJCI Insight, 2007
- Oxidative Phenotype Protects Myofibers from Pathological Insults Induced by Chronic Heart Failure in MiceThe American Journal of Pathology, 2007
- Protein Degradation by the 26S Proteasome System in the Normal and Stressed MyocardiumAntioxidants and Redox Signaling, 2006
- NF-κB activation is required for the development of cardiac hypertrophy in vivoAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyThe New England Journal of Medicine, 1990